Search Within

Hematologic Malignancies, Division of

  1. "Anas Younes"
Formats
  1. Meeting Abstract (152)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (319)
  2. Department of Medicine (319)
  3. Executive Committee, Center for Hematologic Malignancies (319)
  4. Lymphoma (319)
  5. Epidemiology and Biostatistics (82)
  6. Survivorship Research (75)

More Groups

People
  1. Anas Younes (319)
  2. Andrew Zelenetz (88)
  3. Connie Batlevi (81)
  4. David Straus (73)
  5. Matthew Matasar (68)
  6. Anita Kumar (66)

More People

Years
  1. 2024 (2)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (90)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (98)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (319)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maximum tolerated dose (MTD) and safety profile from phase I study of MT-3724 (CD20 targeted immunotoxin) in relapsed/refractory (R/R) non-Hodgkin B-cell lymphoma (NHL)
    Meeting Abstract

    Fanale, M. A.; Park, S. I.; Valacer, D. J.; Higgins, J.; Sloan, J. M.; Younes, A.; Hamlin, P. A.
    Blood (2017)

    Fulltext@MSK | Save
  • Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study
    Meeting Abstract

    Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G.; Fanale, M. A.; Armand, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study
    Meeting Abstract

    Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illes, A.; Picardi, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Active surveillance for newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
    Meeting Abstract

    Borchmann, S.; Joffe, E.; Moskowitz, C. H.; Zelenetz, A. D.; Noy, A.; Portlock, C. S.; Gerecitano, J. F.; Batlevi, C.; Caron, P.; Drullinsky, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic stem cell transplantation outcomes after nivolumab monotherapy for +relapsed/refractory hodgkin lymphoma (CheckMate 039 and CheckMate 205)
    Meeting Abstract

    Carlo-Stella, C.; Collins, G.; Armand, P.; Zinzani, P. L.; Cohen, J. B.; Halwani, A.; Millenson, M.; Provencio, M.; Domingo Domenech, E.; Giulino-Roth, L.; more...
    Bone Marrow Transplantation (2017)

    Fulltext@MSK | Save
  • Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
    Journal Article

    Younes, A.; Salles, G.; Martinelli, G.; Bociek, R. G.; Barrigon, D. C.; González Barca, E.; Turgut, M.; Gerecitano, J.; Kong, O.; Pisal, C. B.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: Results from an expanded phase I trial
    Journal Article

    Oki, Y.; Kelly, K. R.; Flinn, I.; Patel, M. R.; Gharavi, R.; Ma, A.; Parker, J.; Hafeez, A.; Tuck, D.; Younes, A.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: Full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
    Meeting Abstract

    Jäger, U.; Engert, A.; Fanale, M.; Santoro, A.; Armand, P.; Ansell, S.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save